-11.8% · 90d
$5.16
+0.04 (+0.78%)
After-Hours $5.16(+0.00)
News
(1)April 2026
Savara SVRA Sets Annual Meeting Ahead of August FDA Decision
SVRASavara Inc
# 🧾 What This Document Is This is a **preliminary proxy statement** (PRE 14A) for Savara Inc. Think of it as a company's official "meeting invitation and agenda" sent to its owners (stockholders). It explains what will be voted on at the upcoming annual meeting and provides the information needed t
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%